What Is IBB? iShares Biotechnology ETF

IBB is the iShares Biotechnology ETF, launched in February 2001 by BlackRock's iShares unit. It tracks the ICE Biotechnology Index (formerly the Nasdaq Biotechnology Index) and holds around 260 US-listed biotech and pharmaceutical companies, weighted by market cap. It charges a 0.44% expense ratio.

As the oldest and one of the largest biotech ETFs, IBB is widely treated as the benchmark for the sector. Its market-cap weighting means the biggest, most established biotech firms carry the most influence over returns.

Approximate weights as of mid-2026; refresh quarterly from BlackRock (iShares)'s fund page. Each ticker links to its individual stock guide in Walnut.

IBB's portfolio is anchored by large-cap biotech leaders. Top holdings include Vertex Pharmaceuticals near 7.8%, Amgen around 7.7%, Gilead Sciences near 7.1%, and Regeneron around 5%, followed by argenx, Alnylam, and Natera.

Because the fund is market-cap-weighted, its top ten positions represent a large share of assets. That gives IBB a quality tilt toward profitable, cash-generative firms, but it also means a handful of mega-cap names drive much of the fund's day-to-day movement.

The main decision for biotech investors is IBB versus XBI, the SPDR S&P Biotech ETF. IBB is market-cap-weighted, so large profitable biotechs dominate. XBI is equal-weighted, giving small and mid-cap biotechs far more sway and making it more volatile and small-cap-driven.

In rallies led by emerging biotechs and M&A, XBI often outpaces IBB. In risk-off periods, IBB's large-cap tilt tends to hold up better. The two funds have similar fees, so the choice comes down to which slice of the sector you want to emphasize.

IBB's performance tracks the broad biotech cycle, which is driven by clinical trial results, drug approvals, M&A activity, and interest rates. Its large-cap tilt makes it less whipsawed than small-cap-heavy funds but also caps some of the upside in strong biotech bull markets.

The long-term case for biotech rests on innovation in areas like gene therapy, obesity drugs, and oncology, alongside an aging global population. That growth is real but lumpy and event-driven, so IBB can trade in wide ranges for extended periods.

Whether IBB fits depends on your goals, risk tolerance, and time horizon, and Walnut is not an investment adviser. IBB offers broad, liquid, large-cap-tilted access to a single volatile sector, so it is usually held as a satellite position rather than a whole portfolio.

Investors who want steadier biotech exposure often prefer IBB, while those seeking more small-cap growth lean toward XBI. Some hold both. Consider how much single-sector concentration you are comfortable adding before you buy.

IBB trades on the Nasdaq and can be purchased in any standard brokerage account, including Robinhood, Fidelity, Schwab, and Public. Many of these brokers offer fractional shares, so you can add IBB in small dollar amounts.

You can also connect your existing broker to Walnut to track IBB alongside your other holdings and target weights, and see how a biotech sleeve fits your overall plan before adding to it.

IBB is the default core holding for broad US biotech exposure, weighted toward profitable large caps. At 0.44% it is not cheap versus a total-market fund, but it is the liquid, established way to own the sector. Investors wanting more small-cap upside often pair or swap it with the equal-weighted XBI.

Whether IBB is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is IBB a buy?

IBB yields ~0.3% as of mid-2026, paid by passing through the dividends of its underlying holdings. For the payout schedule, history, and how the distributions are taxed, see IBB dividend: yield and schedule.